Trifluridine-Tipiracil

A phase 3 trial designed to assess trifluridine and tipiracil plus bevacizumab as first-line treatment for certain patients with advanced colorectal cancer missed its primary endpoint.

The combination of panitumumab, ipilimumab and nivolumab induced responses among patients with metastatic colorectal cancer, according to phase 2 study results presented at Gastrointestinal Cancers Symposium.